NASDAQ:XBIO Xenetic Biosciences Q1 2025 Earnings Report $2.54 -0.01 (-0.39%) Closing price 07/31/2026 03:50 PM EasternExtended Trading$2.54 0.00 (0.00%) As of 07/31/2026 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Xenetic Biosciences EPS ResultsActual EPS-$0.59Consensus EPS -$0.72Beat/MissBeat by +$0.13One Year Ago EPSN/AXenetic Biosciences Revenue ResultsActual Revenue$0.59 millionExpected Revenue$0.52 millionBeat/MissBeat by +$74.00 thousandYoY Revenue GrowthN/AXenetic Biosciences Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time8:30AM ETUpcoming EarningsXenetic Biosciences' Q2 2026 earnings is estimated for Friday, August 7, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Xenetic Biosciences Earnings HeadlinesXenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...June 4, 2026 | finance.yahoo.comXenetic Biosciences Grants Equity Award to Interim CEOApril 27, 2026 | theglobeandmail.comWhat's the Best Way to Lower RMD Taxes?Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accounts - and without a plan, those required minimum distributions can carry a serious tax cost. SmartAsset's model suggests working with a fiduciary financial advisor could potentially add 36% to 212% more dollar value to a portfolio over a lifetime. Their no-cost tool matches you with vetted advisors in your area who are legally bound to act in your interest.August 2 at 1:00 AM | SmartAsset (Ad)Xenetic extends R&D collaboration with The Scripps Research InstituteNovember 19, 2025 | msn.comXenetic Biosciences Announces Public Offering PricingOctober 14, 2025 | msn.comXenetic 735,000 share Spot Secondary priced at $6.12October 10, 2025 | msn.comSee More Xenetic Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Xenetic Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xenetic Biosciences and other key companies, straight to your email. Email Address About Xenetic BiosciencesXenetic Biosciences (NASDAQ:XBIO) is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders. At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets. By integrating these platforms, the company aims to create therapeutics with enhanced efficacy, favorable dosing profiles and better patient compliance. Xenetic’s lead programs have progressed through preclinical development and early-stage clinical trials, with an emphasis on oncology immunotherapy and enzyme replacement therapies. The company collaborates with academic institutions and industry partners to advance its candidates and to explore new applications of its delivery and targeting technologies. Research and development activities are centralized in the United States, supported by strategic operations in Europe. Headquartered in Boston, Massachusetts, Xenetic is committed to innovation in biologics and small-molecule therapeutics. Led by a team with deep expertise in protein engineering, drug development and regulatory strategy, the company continues to build a pipeline aimed at improving outcomes for patients with serious and life-threatening conditions. Xenetic Biosciences is publicly traded on the NASDAQ under the ticker XBIO.View Xenetic Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Strategy's Structural Strength: Hidden in a $8 Billion IllusionMarketBeat Week in Review – 07/27- 07/31Chevron’s Strong Quarter Shows Why It Still Leads the Energy SectorAbbVie Quietly Solved Its Biggest Problem—Now What?Netflix's Big Sell-Off May Be Sending the Wrong SignalAmazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull CaseApple’s Record Quarter Could Not Outrun Its Guidance Problem Upcoming Earnings Booking (8/3/2026)Marriott International (8/3/2026)Diamondback Energy (8/3/2026)ONEOK (8/3/2026)Williams Companies (8/3/2026)Mitsubishi UFJ Financial Group (8/3/2026)Vertex Pharmaceuticals (8/3/2026)Palantir Technologies (8/3/2026)Spotify Technology (8/4/2026)SpaceX (8/4/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
